Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Interest Income

Income earned on cash, deposits, and investments held by the company.

Evotec SENASDAQ: EVO

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income grows, but more slowly than its trailing trend

Q1 FY2026 interest income of €1.82M rose 49.9% year over year, behind the +124.7% change in trailing-twelve-month interest income. Sequentially, it rose 58.6% from the prior quarter. Over 3 fiscal years it compounded at -20.1% a year.

Context

  • Interest income amounted to 0.6% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +49.9% toward the trailing-twelve-month pace of +124.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€1.82M+58.6% QoQ
Last fiscal yearDec 2025
€4.25M+74.5% YoY
LTMMar 2026
€5.02M+124.7% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.9%——
1 year+74.5%——
3-year CAGR-20.1%——
5-year CAGR——
10-year CAGR——

Interest Income history

EUR · from the income statement

Latest · FY2025
4.25M EUR
Year-over-year change
+74.5%
4-year CAGR
+16.9%

Interest Income vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +124.7% is the highest of 8, against a peer median of -5.1%.
  • Interest income amounts to 0.7% of revenue for EVO, versus a peer median of 2.4%.
EVO Competitors
Interest Income for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TDOCTeladoc Health, Inc.LTM Mar 2026$107.64M USD+92.9%+42.6%4.3%
ALVOAlvotechLTM Mar 2026$105.6M USD-18.9%+501.5%18.9%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$34.81M USD+48.0%+209.8%38.5%
AZTAAzenta, Inc.LTM Sep 2026$17.83M USD-5.1%-25.9%2.9%
PCRXPacira BioSciences, Inc.LTM Mar 2026$17.77M USD-21.7%+71.1%2.4%
NVCRNovoCure LimitedLTM Mar 2026$10.54M USD-71.5%+4.7%1.6%
PHVSPharvaris N.V.LTM Sep 2026€5.68M EUR+0.7%——
EVOEvotec SELTM Mar 2026€5.02M EUR+124.7%-20.1%0.7%
SDGRSchrödinger, Inc.LTM Sep 2026$0 USD——0.0%
HROWHarrow Health, Inc.LTM Mar 2026$0 USD——0.0%
TLRYTilray Brands, Inc.LTM Feb 2026$0 USD—+1.8%0.0%
Peer median (excluding EVO) —-5.1%+42.6%2.4%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue618.03M751.45M781.43M796.97M757.26M
Cost of Revenue466.49M577.38M606.38M682.09M694.6M
Gross Profit151.54M174.07M175.05M114.88M62.66M
Gross Margin24.5%23.2%22.4%14.4%8.3%
Research & Development65.7M76.64M68.53M50.86M74.33M
Selling, General & Admin105.45M156.19M169.61M188.2M123.65M
Operating Expenses110.55M153.22M222.56M257.4M197.97M
Depreciation & Amortization70.4M83.2M92.98M101.62M95.55M
EBITDA316.63M(57.61M)24.13M(80.66M)(13.89M)
EBITDA Margin51.2%-7.7%3.1%-10.1%-1.8%
Operating Income41M20.85M(47.51M)(142.52M)(135.31M)
Operating Margin6.6%2.8%-6.1%-17.9%-17.9%
Interest Income2.27M8.34M9.26M2.44M4.25M
Interest Expense9.25M13.15M11.74M11.7M13.87M
Other Income / Expenses195.98M(174.81M)(33.09M)(51.46M)12M
Income Before Tax236.98M(153.96M)(80.59M)(193.98M)(123.31M)
Pre-Tax Margin38.3%-20.5%-10.3%-24.3%-16.3%
Income Tax Expense21.47M21.7M3.32M2.1M(23.88M)
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Net Margin34.9%-23.4%-10.7%-24.6%-13.1%
EPS (Basic)0.65(0.49)(0.23)(0.56)(0.28)
EPS (Diluted)0.65(0.49)(0.23)(0.56)(0.28)
Weighted Avg Shares332.81M353.35M353.87M353.29M355.16M
Weighted Avg Shares (Diluted)332.81M353.41M353.87M354.59M355.16M

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.